ELEVATE UC open-label extension of etrasimod in moderately to severely active ulcerative colitis

Phase 3, open-label, single-arm trial of etrasimod in autoimmune colitis, sponsored by Arena Pharmaceuticals, Inc. Primary endpoints: Incidence of treatment-emergent adverse events and serious adverse events, Laboratory abnormalities and change from treatment baseline and 1 more. Planned start Jan 2020; status: authorised.